ABSTRACT
The need for chiral fine chemical intermediates has become commonplace today in light of the trend toward single enantiomer drugs manufactured by pharmaceutical companies.
Also, as waste disposal costs skyrocket, processes developed today must emphasize environmental safety. Although, at present, chemical approaches account for the majority of processes to produce fine chemicals, biotransformation steps are making more of an impact and are being integrated into
chemical process sequences, especially where the chirality of the target compound must be maintained.
